Oncology

Overview

The Oncology Research Area has been composed by nine groups addressing main unsolved issues in cancer. The research during this period covered the fields of child and adolescent cancer, melanoma, gynecology, urology, cancer stem cells and the molecular mechanisms of the tumor pathologies. There were also three groups from the CIBBIM-Nanomedicine. These groups studied the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics. During the last years the Area has been very active at shared activities such as the virtual AACR yearly meeting, the internal and external ONCO-VHIR seminars and the organization of other periodic topic-based workshops and leisure and team-building activities. This year the Area also organized a World Cancer Day event to get closer to the society. During the mentioned period most groups of the Area have participated in the In-Campus multidisciplinary Task Force Groups for different tumors (gastric, prostate, melanoma, ginecology etc. with the specialized pathologist also involved) that have been fueled by VHIR-VHIO-Hospital. It is also noteworthy the shared scientific production in terms of publications between different groups of the Area and the stable collaborations between groups that have consolidated during these period.

Publications

141

total

748

impact factor

5.30

average impact factor

Group Leaders: Soledad Gallego and Josep Sánchez de Toledo

team

group-zoom

zoom

group-download

download

In 2019, the group of Translational Research in Child and Adolescent Cancer consolidated their research lines, namely on Soft Tissue Sarcomas (e.g. Rhabdomyosarcoma and other childhood sarcomas), Neural tumours (e.g. Neuroblastoma, Ependymoma) and the program of personalized medicine. This research yielded the publication of 34 new international papers with an accumulated impact factor (JCI 2017) of 217.7. The group was awarded with 2 new grants from La Marató TV3, and one innovation grant (LLAVOR) from AGAUR, The group has continued with the consolidated collaborations with biotech companies to test and develop new therapies against the most aggressive pediatric solid tumors, with 2 new patents registered in 2019.

Furthermore, the group is currently running 42 clinical trials with the most advanced treatments for childhood tumors.

27

total

200

impact factor

7^.39

average impact factor

SELECTED ARTICLES

Bisogno G, De Salvo GL, Bergeron C, Gallego Melcon S, Merks JH, Kelsey A, Martelli H, Minard-Colin V,Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben-Arush M, Mudry P, Ferman S, Jenney M, Ferrari A, European paediatric Soft tissue sarcoma Study Group
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2019 Nov;20(11):1566-1575.
DOI: 10.1016/S1470-2045(19)30617-5. Epub 2019 Sep 24.
IF : 35,39
Rio P, Navarro S, Wang W, Sanchez-Dominguez R, Pujol RM, Segovia JC, Bogliolo M, Merino E, Wu N, Salgado R, Lamana ML, Yañez RM, Casado JA, Giménez Y, Román-Rodríguez FJ, Álvarez L, Alberquilla O, Raimbault A, Guenechea G, Lozano ML, Cerrato L, Hernando M, Gálvez E, Hladun R, Giralt I, Barquinero J, Galy A, García de Andoín N, López R, Catalá A, Scwartz JD, Surrallés J, Soulier J, Schmidt M, Diaz de Heredia C, Sevilla J, Bueren JA.
Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia.
Nat Med. 2019 Sep;25(9):1396-1401.
DOI: 10.1038/s41591-019-0550-z. Epub 2019 Sep 9.
IF : 30,6
Qadeer ZA, Valle-Garcia D, Hasson D, Sun Z, Cook A, Nguyen C, Soriano A, Ma A, Griffiths LM, Zeineldin M, Filipescu D, Jubierre L, Chowdhury A, Deevy O, Chen X, Finkelstein DB, Bahrami A, Stewart E, Federico S, Gallego S, Dekio F, Fowkes M, Meni D, Maris JM, Weiss WA, Roberts SS, Cheung NV, Jin J, Segura MF, Dyer MA, Bernstein E.
ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.
Cancer Cell. 2019 Nov 11;36(5):512-527.e
DOI : 10.1016/j.ccell.2019.09.002
IF : 23.916.
Soriano A, Masanas M, Boloix A, Masiá N, París-Coderch L, Piskareva O, Jiménez C, Henrich KO, Roma J, Westermann F, Stallings RL, Sábado C, de Toledo JS, Santamaria A, Gallego S, Segura MF.
Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma.
Cell Mol Life Sci. 2019 Jun;76(11):2231-2243.
DOI : 10.1007/s00018-019-03041-4
IF : 7,014
Anvar Z, Acurzio B, Roma J, Cerrato F, Verde G.
Origins of DNA methylation defects in Wilms tumors.
Cancer Lett. 2019 Aug 10;457:119-128.
DOI: 10.1016/j.canlet.2019.05.013.
IF : 6,491

View all publications